1. Introduction {#s0005}
===============

*P16* (*CDKN2A*) is the most frequently deleted locus in cancer genomes and has been studied extensively ([@bb0015], [@bb0095], [@bb0075], [@bb0080]). While genetic alterations in *P16* do occur, gene methylation is far more prevalent in human cancers such as oral squamous cell carcinoma (OSCC) ([@bb0110], [@bb0130], [@bb0065], [@bb0055], [@bb0090]). Studies have also shown that increased *P16* methylation correlates with decreased levels of expression and has been linked to the development and prognosis in many cancers ([@bb0135], [@bb0010], [@bb0105], [@bb0060], [@bb0035]). *P16* methylation may also play important roles in carcinogenesis ([@bb0145]).

Oral leukoplakia is the most common precancerous condition ([@bb0085]). Studies have shown that 17--25% of oral leukoplakia lesions contain oral epithelial dysplasia (OED), and about 8% will progress to OSCC ([@bb0020], [@bb0025]). The *P16* inactivation rate in end-stage head and neck carcinomas has been reported to be as high as 70--85% ([@bb0030], [@bb0120], [@bb0125], [@bb0040]). One study found that the *P16* methylation rate (58%) was much higher than the *P16* mutation rate (15%) in 28 severe OED lesions ([@bb0090]). *P16* methylation is also frequently detected in mild/moderate OED lesions (25--40%) and may be associated with an increased risk of progression ([@bb0060], [@bb0035]). However, the feasibility of using *P16* methylation to predict malignant progression of OED has not yet been validated in a multicenter study. Therefore, such a study among Chinese patients with OED was carried out using *P16* methylation as a clinical classifier. This study provides evidence strongly supporting that *P16* methylation could be used as a biomarker for predicting the malignant transformation of OED early in the course of the disease.

2. Methods {#s0010}
==========

2.1. Study Design {#s0015}
-----------------

181 patients with mild or moderate OED were selected from cases of oral leukoplakia, lichen planus, or chronic discoid erythematosus at Peking University School of Stomatology (Central-A, n = 82), Capital Medical University School of Stomatology (Central-B, n = 68), and Fourth Military Medical University Hospital of Stomatology (Central-C, n = 31) between 2009 and 2011. The biopsy specimens were fixed in neutral buffered formalin, embedded in paraffin, and stained with H&E. The baseline OED lesions were classified as mild, moderate, or severe by at least two senior pathologists using the same criteria from the 2005 WHO Classification System ([@bb0050]). The sample size was calculated according to results of our previous single center study ([@bb0035]).

All cases involved primary lesions with no prior surgical, LASER, radiation therapy, or chemotherapy treatments. Information on clinical variables, lesion site, cigarette smoking, alcohol use, and past medical history was also collected. Follow-up examination was regularly performed every three months in a double-blind pattern for at least three years as described previously ([@bb0035]). If malignant development was observed, an additional examination and re-biopsy were carried out. Patients who did not require a re-biopsy during the follow-up examination period due to an obvious disappearance/regression of the baseline lesion continued to undergo extensive examinations ([Fig. 1](#f0005){ref-type="fig"}). The study was approved by the Institutional Review Boards of the Peking University Cancer Hospital, and all patients gave written informed consent. This trial is registered in the U.S. National Institutes of Health Clinical Trials Protocol Registration System in accordance with the criteria outlined by the International Committee of Medical Journal Editors (trial number [NCT01695018](ctgov:NCT01695018){#ir0015}, available at <http://ClinicalTrials.gov>).

2.2. Quantification of *P16* Methylation Using the 115-bp MethyLight {#s0020}
--------------------------------------------------------------------

Genomic DNA from the OED biopsy samples was extracted from the frozen tissues or paraffin blocks ([@bb0035]). Genomic DNA samples (2 μg) were treated with 5 M sodium bisulfite for 16 h at 50 °C without desulfonation as described. The proportion of 115-bp methylated fragments from the sense-strand of *P16* exon-1 copies was analyzed using the 115-bp MethyLight assay previously established to quantify the *P16* methylation level for clinical diagnosis ([@bb0150]), however, uracil DNA glycosylase and dUTP were not added into the reaction mixture. The 115-bp sense-fragment is completely included within *P16* exon-1, the most prevalent sequence investigated for *P16* methylation. Methylation in this region is not only correlated with inactivation of this gene ([@bb0065]), but also associated with prognosis of epithelial dysplasia ([@bb0135], [@bb0035], [@bb0150]). Briefly, the 115-bp methylated fragment in the sense-strand of *P16* exon-1 was amplified using forward primer (5′-**CgCg**gt**Cg**tggttagttagt-3′), reverse primer (5′-ta**cG**ct**cG**a**cG**acta**Cg**aaa-3′), and *P16*-specific probe (6FAM-gttgttttt**Cg**t**Cg**t**Cg**gtt-TAMRA). The 25 μl MethyLight reaction mixture contained 12.5 μl Maxima Probe/ROX qPCR Master Mix (2 ×) (\#K0233, Thermo Scientific Fermentas Mix), 0.75 μl of 10 μmol/L of each primer (TaKaRa, Beijing), 0.75 μl of 10 μmol/L probe (TaKaRa), and 8 ng of template. An ABI7500 fast thermal cycler was used to perform the PCR reactions using the following thermal conditions: 37 °C for 10 min → 95 °C for 30 min → (95 °C for 15 s → 62 °C for 1 min) × 45 cycles. The fluorescence signal was detected at 62 °C. Samples were run in duplicate, and the average Ct value was calculated. The *COL2A1* gene, a CpG island-free gene whose copy number was not effected by methylation status in the MethyLight assay, was used as input reference and amplified with forward primer (5′-tctaacaattataaactccaaccaccaa-3′), reverse primer (5′-gggaagatgggatagaagggaatat-3′), and *COL2A1*-specific probe (6FAM-ccttcattctaacccaatacctatcccacctctaaa-BHQ1) ([@bb0140]). Relative copy number (RCN) of methylated-*P16* was calculated according to the formula \[2^− ΔCt^, (ΔCt = Ct~*methylated*-*P16*~ − Ct*~COL2A1~*)\]. Genomic DNA samples from the human colon cancer cell line RKO containing completely methylated *P16* alleles and *P16* unmethylated MGC803 cell xenografts were used as *P16* methylation-positive and -negative controls for each experiment, respectively ([@bb0035]). These cell lines were tested and authenticated by Beijing Jianlian Genes Technology Co., Ltd before being used in this study as we described previously ([@bb0100]).

2.3. Determining *P16* Methylation State Definition {#s0025}
---------------------------------------------------

In order to steadily detect fluorescence signal for methylated-*P16* at the proportion of 1/64 (1.56%), each MethyLight reaction (25 μl) should contain at least 8 ng bisulfite-modified template DNA that would result in the Ct value for the input reference *COL2A1* ≤ 29.3. Using less template DNA would lead to false methylation-negative results. Therefore, when the cutoff value for *P16* methylation-positive was set at 1/64, only DNA samples with an average *COL2A1*-Ct value ≤ 29.3 were considered as *P16* methylation-informative. All of the frozen samples and 80% of the paraffin embedded samples met the *P16* methylation-informative cut-off. When an amplification signal for the methylated-*P16* is detected in the informative samples, it is defined as *P16* methylation-positive; otherwise, it is considered *P16* methylation-negative.

2.4. P16 Immunohistochemical Staining (IHC) {#s0030}
-------------------------------------------

Mouse monoclonal antibody against human P16 protein (ZM-0205, ZYMED, USA) and the 2-step plus poly-HRP anti-mouse IgG detection system (PV-9000, GBI, USA) were used to stain oral mucosal biopsy slides according to the manufactures\' protocol. Slides were then counterstained with hematoxylin.

2.5. Statistical Analysis {#s0035}
-------------------------

Results were displayed by constituent ratios of enumeration or ranked data. SPSS 13.0 software was used to perform univariate and multivariate analyses with the Chi Square test and binary logistic regression analysis. Student\'s *t*-test was used to analyze age data. All P-values were two-sided, and P \< 0.05 was considered statistically significant. Each biopsy at baseline and follow-up analysis was assigned a severity score according to its histopathologic diagnosis: 1 for carcinoma, 2 for severe grade OED, 3 for moderate grade OED, 4 for mild OED, 5 for hyperplasia, and 6 for normal.

3. Results {#s0040}
==========

3.1. Demographics and Clinical Characteristics of the Patients {#s0045}
--------------------------------------------------------------

Of the baseline mild and moderate OED cases, 152 of 181 cases met the criteria to appropriately classify the *P16* methylation state using the 115-bp MethyLight analysis (*COL2A1*-Ct value ≤ 29.3) and 29 cases were classified as non-methylation-informative ([Fig. 1](#f0005){ref-type="fig"}). 5 methylation-negative cases were lost during the follow-up period because of changes of contact information. Thus, 147 cases with follow-up information were ultimately enrolled into the final cohort analysis giving an overall compliance of 96.7%. 48 samples were ultimately classified as *P16* methylation-positive. The average age of patients with *P16* methylation-positive OED was significantly higher than that of the *P16* methylation-negative patients (59.3 years *vs* 54.7 years, Student\'s *t*-test, P = 0.011; [Table 1](#t0005){ref-type="table"}). Most patients with a positive smoking (40/43) or drinking history (23/26) were male.

Malignant transformation of OED to OSCC was observed in 21 of 147 (14.3%) patients during the follow-up (range, 3 to 129 months; *median*, 41 months) ([Supplementary figure](#f0025){ref-type="fig"}). The average baseline age of the patients that underwent malignant progression was similar to that of patients that remained stable (56.5 years *vs* 56.1 year). The overall cancer rate was significantly higher in females than males (21.0% *vs* 6.1%, Chi-square test, P \< 0.020; [Table 2](#t0010){ref-type="table"}). Similarly, OED lesions of the tongue showed significantly higher rates of cancer progression than those at other sites (23.9% *vs* 5.3%; P \< 0.003). Interestingly, the risk of OSCC development was slightly increased in these patients without smoking and alcohol use history.

Next, the expression status of P16 in representative OED and OSCC samples was analyzed using the IHC assay ([Fig. 2](#f0010){ref-type="fig"}). Results of IHC analysis showed that P16 protein was located in both the cytoplasm and nucleus of epithelial cells in OED lesions, but only in the cytoplasm of OSCC cells. Additionally, a greater quantity of P16-positive staining epithelial cells was observed in the *P16* methylation-negative samples than in the *P16* methylation-positive samples.

3.2. *P16* Methylation Is an Early Predictor for Malignant Progression of OED {#s0050}
-----------------------------------------------------------------------------

The rate of progression of OED to OSCC in the 48 *P16* methylation-positive patients was consistently higher than that of 99 *P16* methylation-negative patients when analyzing different subgroups including: sex, age, baseline grade, lesion site, center, and specimen storage medium. Multivariate analysis showed that the risk of malignant transformation for *P16* methylation-positive OEDs was significantly higher than the negative OEDs after adjustment for age, sex, smoking, alcohol use, lesion site, and OED grade (adjusted odds ratio = 4.28, 95% confidence interval \[CI\]: 1.42--12.87; P = 0.002) ([Table 2](#t0010){ref-type="table"}). The malignant transformation Kaplan--Meier curve for patients with *P16* methylation-positive OED was also significantly different from those with the *P16* methylation-negative OED (log-rank test, P = 0.002; [Fig. 3](#f0015){ref-type="fig"}).

The area under the receiver operating characteristic curve (ROC) is 0.693 (95% CI: 0.56--0.83; P = 0.005; [Fig. 4](#f0020){ref-type="fig"}). Using a relative copy number cutoff point of 8.21 × 10^− 5^, the sensitivity and specificity for early prediction of OED malignant transformation using the *P16* methylation-positive classification as a biomarker were 62% (13/21) and 76% (96/126), respectively.

4. Discussion {#s0055}
=============

Early prediction of the malignant potential of OED is crucial for clinical management of patients with the disease. Since methylation changes occurring in only a small number of cells can now be sensitively detected in tissues containing multiple cell types, alterations in promoter methylation may ultimately offer optimal biomarkers for predicting the malignant potential of precancerous lesions ([@bb0045]). In this multicentre prospective study, we observed that *P16* methylation was a significant, independent predictor of malignant progression of OED with a sensitivity and specificity of 62% and 76%, respectively. This is consistent with the results of two small single-center studies in China and Britain ([@bb0060], [@bb0035]). Collectively, these studies indicate that *P16* methylation significantly correlates with malignant progression of OED and could be used as a useful biomarker for personalizing the management of patients with this disease.

In regular methylation analysis using MSP and other PCR-based methylation assays, a tested sample is generally considered methylation-informative after a PCR product for the methylated- or unmethylated-fragment of CpG islands is obtained. However, we found that the quantity of input DNA was a crucial factor in accurately determining the level of *P16* methylation in paraffin embedded samples when using the MethyLight assay. We found that at least 8 ng of bisulfite-modified, single-stranded DNA in the 25 μl MethyLight reaction mixture was required to generate Ct values for the input reference *COL2A1* \< 29.3, which allowed the proportion of 1/64 of methylated-*P16* to be consistently detected. Therefore, in order to ensure accurate results, only samples with the reference Ct value \< 29.3 were considered as *P16* methylation-informative. The significance of this finding is that sufficient amounts of input DNA are required for all accurate quantitative methylation analyses.

The proportion of 1/64 (or higher) of methylated-*P16* indicates that at least 1.56% of input cells may be malignantly transformed. However, increasing the amount of input DNA could increase the number of samples detected as methylation-positive, especially for paraffin samples containing \< 1.56% *P16*-methylated cells. Therefore, because it is unknown if OEDs containing \< 1.56% methylated-*P16* have a higher risk of malignant progression when compared to OEDs with no methylated-*P16*, we could not exclude that a *P16* methylation-positive classification for this part of samples could be clinically false methylation-positive.

Although the average age of the *P16* methylation-positive patients was higher than that of *P16* methylation-negative patients, multivariate analysis revealed that *P16* methylation is still significantly associated with malignant transformation of OEDs after adjusting for age. This indicates that *P16* methylation is an independent predictor of this disease prognosis.

It is well known that 5-methylcytosine in DNA may further be oxidized into hydroxymethylation, which cannot be distinguished from true methylation using regular methylation assays. We have recently reported hydroxymethylation of *P16* CpG islands in cancer cells [@bb0115] and observed that *P16*-specific hydroxymethylation can reactivate transcription of methylated-*P16* alleles (unpublished data; Deng D et al.). It is necessary to further clarify if combined analysis of both true *P16* methylation and hydroxymethylation (or other derivatives) might improve clinical performance of the methylation marker. The causality of *P16* methylation with OSCC development also requires further study.

An Italian group has reported that there is no eminent benefit to surgical intervention of OED in preventing recurrences and malignant development ([@bb0005]). In our previous study, we described that the risk of cancer progression in OED patients with surgical excision was even slightly higher than those without surgical excision, especially in patients with *P16* methylation-positive OED ([@bb0035]). Therefore, surgical intervention might need to be avoided in the management for mild and moderate OED patients. Only OED patients without surgical excision were included in the present multicentre prospective study.

Ho M et al. have reported that non-smoking status is a significant predictor for malignant transformation of OED patients in the UK ([@bb0070]). In the present study, OED patients with a negative smoking or alcohol use history showed a higher OSCC progression rate than patients with a positive history, although the difference in cancer risk was not significant.

In conclusion, *P16* methylation could be used as an additional tool in helping to predict the malignant potential of OED. Combined with other diagnostic and prognostic factors, *P16* methylation could help to shape an individualized treatment plan for OED patients. While it is still unknown if these results can be generalized across all populations, detection of *P16* methylation should be carried out at least for Chinese OED patients.

The following is the supplementary data related to this article.Supplementary figurePhotos of the baseline oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC) from two representative samples. H&E-stained; white bar: 50 μm.

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.ebiom.2015.03.015](10.1016/j.ebiom.2015.03.015){#ir0025}.
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![Participant flow diagram.](gr1){#f0005}

![P16 immunohistochemical staining images. Photos of the baseline oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC). A, B, and C: OED lesions with strong, weak, and negative P16 staining in the cytoplasm and nucleus of squamous epithelial cells, respectively; D and E: OSCC with extensively and focally moderate staining in the cytoplasm of cancer cells, respectively; A, B, D: *P16* methylation-negative; C and E: *P16* methylation-positive; F: P16-negative control, an xenograft originated from human colon cancer cell line RKO containing only silenced *P16* alleles by methylation; white black bar: 60 μm.](gr2){#f0010}

![Malignant transformation Kaplan--Meier curves for patients with *P16* methylation-positive and negative oral epithelial dysplasia. The log-rank test, P = 0.002.](gr3){#f0015}

![ROC curve of prediction of malignant progression of oral epithelial dysplasia by different *P16* methylation levels. The area under the curve is 0.693 (95% CI: 0.56-0.83, P = 0.005). Green dot, cutoff point of relative copy number of methylated-*P16*, 8.21 × 10^− 5^.](gr4){#f0020}

###### 

Demographic and clinical characteristics of the patients with oral epithelial dysplasia enrolled into the final follow-up analysis.

  Status of *p16* methylation   n     Age (years)   Sex                                                        
  ----------------------------- ----- ------------- ---------------------------------------------- ----------- -----------
  Methylation-positive          48    25--78        59.3 ± 10.4[⁎](#tf0005){ref-type="table-fn"}   20 (41.7)   28 (58.3)
  Methylation-negative          99    33--77        54.7 ± 11.2                                    46 (46.5)   53 (53.5)
  (Total)                       147   25--78        56.2 ± 11.1                                    66 (44.9)   81 (55.1)

Methylated group vs. unmethylated group, Student\'s *t*-test, P = 0.011.

###### 

Comparison of *P16* methylation-positive rate and malignant transformation of oral epithelial dysplasia between different subgroups with and without *P16* methylation (*P16* M) in univariate and multivariate analyses.

  Item                All cases   *P16* M-positive cases   *P16* M-negative cases   Odd ratio in univariate analysis (95% CI)                                                                    
  ------------------- ----------- ------------------------ ------------------------ ------------------------------------------- ----------- ----------- ---------- ----------------------------- -------------------------
  Sex                 Male        66                       30.3%                    **6.1%**                                    20          3 (15.0)    46         1 (2.2)                       
  Female              81          34.6%                    **21.0%^a,d^**           28                                          10 (35.7)   53          7 (13.2)   **3.65 (1.06--12.82)**        
  Age (y)             \< 60       93                       29.0%                    14.0%                                       27          8 (29.6)    66         5 (7.6)                       **5.14 (1.31--20.97)**
  ≥ 60                54          38.9%                    14.8%                    21                                          5 (23.8)    33          3 (9.1)                                  
  Cigarette smoking   Yes         43                       30.2%                    7.0%                                        13          2 (15.4)    30         1 (3.3)                       
  No                  104         33.7%                    17.3%                    35                                          11 (31.4)   69          7 (10.1)   **4.06 (1.26--13.36)**        
  Alcohol use         Yes         26                       26.9%                    3.8%                                        7           1 (14.3)    19         0                             
  No                  121         33.9%                    16.5%                    41                                          12 (29.3)   80          8 (10.0)   **3.72 (1.25--11.29)**        
  Baseline grade      Mild        97                       32.0%                    16.5%                                       31          11 (35.5)   66         5 (7.6)                       **6.71 (1.85--25.65)**
  Moderate            50          34.0%                    10.0%                    17                                          2 (11.8)    33          3 (9.1)                                  
  Lesion sites        Tongue      71                       40.8%                    **23.9%^b,e^**                              29          11 (37.9)   42         6 (14.3)                      **3.67 (1.03--13.52)**
  Others              76          25.5%                    **5.3%**                 19                                          2 (10.5)    57          2 (3.5)                                  
  Central             A           69                       36.2%                    10.1%                                       25          6 (24.0)    44         1 (2.3)                       **13.58 (1.43--320.9)**
  B                   62          29.0%                    19.4%                    18                                          6 (33.3)    44          6 (13.6)                                 
  C                   16          31.3%                    12.5%                    5                                           1 (20.0)    11          1 (9.1)                                  
  Sample storages     Frozen      41                       31.7%                    9.8%                                        13          4 (30.8)    28         0                             Undefined
  Paraffin            106         35.7%                    16.0%                    35                                          9 (25.7)    71          8 (11.3)                                 
  (Total)             147         32.7%                    14.3%                    48                                          13 (27.1)   99          8 (8.1)    **4.22 (1.47--12.35)^c,f^**   

^a,b,c^Differences of cancer rates between two subgroups are statistically significant in univariate analysis (Fisher\'s exact test, P = 0.020, 0.003, 0.002, two sides, respective. ^d,e,f^Adjusted odds ratio: 3.41 (95% CI: 0.66--17.72), 4.75 (1.31--17.16), 3.64 (1.29--10.27), respectively, after sex, age, smoking, alcohol use, lesion site, and OED grade were adjusted in multivariate analysis. The values are presented in the bold letters when difference between two subgroups is statistically significant.
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